Amendments To The Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-53. (Canceled)

54. (Currently amended) A pharmaceutical composition comprising an effective amount of ~~a combination of ATP-depleting agents at concentrations which deplete the ATP level to 15% or less of normal in cancer cells, wherein the combination comprises~~ 6-methylmercaptopurine riboside (MMPR), 6-[[A]]aminonicotinamide (6-AN), ~~and~~ N-(phosphonacetyl)-L-aspartic acid (PALA), dehydroepiandrosterone (DHEA), and oxythiamine (OT), in combination with a pharmaceutically acceptable carrier ~~and wherein the cancer cells are breast, ovarian or pancreatic cancer cells~~.

55. (Currently amended) A pharmaceutical composition comprising an effective amount of ~~a combination of ATP-depleting agents at concentrations which deplete the ATP level to 15% or less of normal in cancer cells, wherein the combination comprises~~ N-(phosphonacetyl)-L-aspartic acid (PALA), alanosine (AL), ~~and~~ 6-methylmercaptopurine riboside (MMPR), and 3-bromopyruvate (BrPA), in combination with a pharmaceutically acceptable carrier ~~and wherein the cancer cells are breast, ovarian or pancreatic cancer cells~~.

56-58. (Canceled)

59. (Currently amended) The composition of claim 55, ~~wherein the combination~~ further comprising ~~comprises~~ Adriamycin, and wherein the amount of Adriamycin administered is one-half the maximum tolerated dosage.

60. (Currently amended) The composition of claim 54, ~~wherein the combination~~ further comprising ~~comprises~~ BrPA and Adriamycin, and wherein the amount of Adriamycin administered is one-half the maximum tolerated dosage.

61. (Currently amended) The composition of claim 55, ~~wherein the combination~~ further comprising ~~comprises~~ 4[(1E)-2-(1H-indol-3-yl)ethenyl]-1-methyl-pyridinium iodide ~~F16~~.

62. (Currently amended) The composition of claim 54, ~~wherein the combination~~ further comprising ~~comprises~~ 4[(1E)-2-(1H-indol-3-yl)ethenyl]-1-methyl-pyridinium iodide ~~F16~~.

63-64. (Canceled)

65. (New) A method for treating a subject having a cancer selected from the group consisting of breast cancer, ovarian cancer or pancreatic cancer, comprising administering to the subject the following combination of agents:

(i) 6-methylmercaptopurine riboside (MMPR);
(ii) 6-aminonicotinamide (6-AN);
(iii) N-(phosphonacetyl)-L-aspartic acid (PALA);
(iv) dehydroepiandrosterone (DHEA) and

(v) oxythiamine (OT),

wherein said combination of agents is administered concurrently or sequentially.

66. (New) The method of 65 further comprising 4[(1E)-2-(1H-indol-3-yl)ethenyl]-1-methyl-pyridinium iodide.

67. (New) A method for treating a subject having a cancer selected from the group consisting of breast cancer, ovarian cancer or pancreatic cancer, comprising administering to the subject the following combination of agents:

(i) N-(phosphonacetyl)-L-aspartic acid (PALA);
(ii) alanosine (AL);
(iii) 6-methylmercaptopurine riboside (MMPR) and
(iv) 3-bromopyruvate (BrPA),

wherein said combination of agents is administered concurrently or sequentially.

68. (New) The method of 67 further comprising Adriamycin, and wherein the amount of Adriamycin administered is one-half the maximum tolerated dosage.

69. (New) The method of 65 further comprising BrPA and Adriamycin, and wherein the amount of Adriamycin administered is one-half the maximum tolerated dosage.

70. (New) The method of 67 further comprising 4[(1E)-2-(1H-indol-3-yl)ethenyl]-1-methyl-pyridinium iodide.